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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective medical
therapies. Recent research has focused on identifying the biological processes essential to the development and
progression of fibrosis, and on the mediators driving these processes. Lysophosphatidic acid (LPA), a biologically
active lysophospholipid, is one such mediator. LPA has been found to be elevated in bronchoalveolar lavage (BAL)
fluid of IPF patients, and through interaction with its cell surface receptors, it has been shown to drive multiple
biological processes implicated in the development of IPF. Accordingly, the first clinical trial of an LPA receptor
antagonist in IPF has recently been initiated. In addition to being a therapeutic target, LPA also has potential to be
a biomarker for IPF. There is increasing interest in exhaled breath condensate (EBC) analysis as a non-invasive
method for biomarker detection in lung diseases, but to what extent LPA is present in EBC is not known.
Methods: In this study, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assess for the
presence of LPA in the EBC and plasma from 11 IPF subjects and 11 controls.
Results: A total of 9 different LPA species were detectable in EBC. Of these, docosatetraenoyl (22:4) LPA was
significantly elevated in the EBC of IPF subjects when compared to controls (9.18 pM vs. 0.34 pM; p = 0.001). A total
of 13 different LPA species were detectable in the plasma, but in contrast to the EBC, there were no statistically
significant differences in plasma LPA species between IPF subjects and controls.
Conclusions: These results demonstrate that multiple LPA species are detectable in EBC, and that 22:4 LPA levels
are elevated in the EBC of IPF patients. Further research is needed to determine the significance of this elevation of
22:4 LPA in IPF EBC, as well as its potential to serve as a biomarker for disease severity and/or progression.
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Background
Idiopathic pulmonary fibrosis is a progressive and ultim-
ately fatal disease in which normal lung is replaced by fi-
brous scar tissue. The cause of the disease is unknown;
however, exposure to refluxed gastric acid, occupational
exposures, and viral infections have been postulated as in-
citing insults [1-3]. The average duration from diagnosis
to time of death is 2–3y e a r s[ 4 ] .D i a g n o s i si sm a d ee i t h e r
by pathology consistent with usual interstitial pneumonia
or radiographic findings showing areas of fibrosis and
honeycombing in the absence of an alternate diagnosis
[5]. Once the diagnosis of IPF is made limited options
exist for treatment except for lung transplantation.
Recent advances have occurred in our understanding
of the mechanisms involved in IPF pathogenesis. Specif-
ically, aberrant wound healing responses to tissue injury,
such as epithelial cell apoptosis, increased vascular per-
meability, extravascular coagulation, and fibroblast mi-
gration and activation, have all been implicated in the
development of lung fibrosis [6,7]. Research efforts have
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progression from normal to fibrotic lung, as a better un-
derstanding of such pathways may provide potential tar-
gets for pharmacologic therapy and biomarkers to aid in
diagnosis or prognosis [7]. One such area of interest in-
volves the role of lysophosphatidic acid (LPA) in the de-
velopment and progression of pulmonary fibrosis.
LPA is a biologically active lysophospholipid that has
been shown to mediate numerous biological processes
thought to contribute to tissue fibrosis [7]. Structurally,
LPA consists of glycerol-phosphate with a single fatty
acid esterified at the sn-1o rsn-2 position. There are nu-
merous LPA species present in biological fluids, identi-
fied by the length and degree of saturation of the fatty
acid moiety [8]. The majority of extracellular LPA is pro-
duced from lysophosphatidylcholine (LPC) by the en-
zyme autotaxin (also known as lysophospholipase D)
[9,10]. LPA’s activity is mediated by interaction with spe-
cific G protein-coupled receptors, six of which have been
definitively identified (LPA1-6) [7,11,12]. The role of LPA
and its receptors has been investigated in the develop-
ment of fibrosis in multiple organ systems, including the
lung, liver, kidneys, skin and peritoneum [13-17]. In the
setting of lung injury, LPA has been shown to contribute
to epithelial cell death, increased vascular permeability,
and fibroblast migration and persistence via interaction
with the LPA1 receptor, and genetic deficiency or pharma-
cologic inhibition of LPA1 confers protection against
bleomycin-induced lung fibrosis in mice [13,18,19]. Fur-
thermore, LPA is elevated in the BAL fluid of IPF patients
and contributes to fibroblast migration into the injured
airspaces in this disease [13]. Based on the apparent im-
portance of the LPA-LPA1 pathway for the development
of lung fibrosis, a Phase II clinical trial of an oral LPA1 an-
tagonist for the treatment of IPF has recently been initi-
ated (ClinicalTrials.gov identifier: NCT01766817). Recent
evidence indicates that the LPA2 receptor can also mediate
profibrotic effects of LPA, such as activation of latent
transforming growth factor-β (TGF-β), and genetic defi-
ciency of this receptor also results in protection against
the development of lung fibrosis in mice [13,20,21].
Given its potentially important and central role in the
development of pulmonary fibrosis, LPA is not only a
therapeutic target but also a potential biomarker in IPF.
While elevated LPA levels have been detected in the
BAL from IPF patients [13], the extent to which LPA is
present and detectable in exhaled breath condensate
(EBC) is not known. EBC has become an area of interest
for potential biomarker analysis in respiratory diseases
[22]. Collection of EBC can be performed in a low-cost
and non-invasive manner. For the detection of certain
biologic molecules, correlation has been demonstrated be-
tween EBC and BAL results, though further research is
needed [23]. In addition to volatile gases, EBC contains
nonvolatile particles representing airway and alveolar lin-
ing fluid contents [24]. The ability to analyze components
from the lining of the respiratory epithelium offers great
potential for biomarker discover. EBC has been studied in
different respiratory diseases, including asthma and COPD
[25,26]. However, few studies have analyzed EBC in the
setting of interstitial lung disease, specifically IPF [27,28].
If LPA were detectable in EBC, it may provide information
about the disease and/or the disease course. In this study
we sought to assess for the presence of LPA in plasma and
EBC and determine if differences exist in the amount of
LPA in subjects with IPF versus controls.
Methods
Study subjects
Subjects with IPF were identified from those being cared
for in the Massachusetts General Hospital (MGH) out-
patient pulmonary clinic or inpatient pulmonary consult
service. For inclusion in this study, subjects had to meet
criteria for a diagnosis of IPF based on the recent joint
consensus statement of the American Thoracic Society
(ATS), European Respiratory Society (ERS), Japanese
Respiratory Society (JRS), and Latin American Thoracic
Association (ALAT) [5]. Controls were recruited through
the Partners Healthcare System Research Study Volunteer
Program (RSVP). Controls were non-smoking individuals
at least 50 years of age without a history of chronic lung
disease. Study approval was obtained through the Partners
Institutional Review Board, and informed consent was ob-
tained on all subjects. Eleven IPF subjects and eleven con-
trols were included in this study. EBC was obtained on all
subjects, and plasma was obtained on all 11 IPF patients
and 10 of the controls.
Exhaled breath condensate (EBC) collection
EBC was collected using the handheld RTube™ exhaled
breath condensate collector (Respiratory Research, Inc.),
according to the manufacturer’s instructions, and follow-
ing the ATS/ERS methodological recommendations for
EBC collection [29]. Collection was performed during 10
minutes of tidal breathing, with a nose clip in place,
using a cooling chamber pre-cooled to −20°C. EBC sam-
ples were placed in aliquots and immediately frozen and
stored at −80°C until analysis.
Plasma collection
Blood was obtained via venipuncture into tubes contain-
ing CTAD (citrate-theophylline-adenosine-dipyridamole)
additive, in order to potently inhibit platelet activation,
as activated platelets are known to release abundant
amounts of LPA [30]. Within 30 minutes of collection,
whole blood was centrifuged at 1500 × g for 15 minutes
to obtain plasma, which was then placed in aliquots and
immediately frozen and stored at −80°C until analysis.
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EBC samples were subjected to lipid extraction using the
modified Bligh and Dyer method as described [31,32].
Briefly, lipid extraction was initiated by adding 2 ml
methanol and 1 ml chloroform to 0.5 ml EBC, followed by
the addition of 2 pmol C17-LPA (internal standard; Avanti
Polar Lipids, Alabaster, AL, USA). Extraction was allowed
for 30 minutes with the samples kept on ice. Then, phase
separation was achieved by adding 1 ml chloroform and
1.3 ml 0.1 N HCl with vigorous vortexing. The chloroform
phase was collected, the solvent was evaporated under a
stream of nitrogen gas, and residues were dissolved in
methanol and transferred into autosampler vials for LC-
MS/MS analysis.
Measurement of LPA species by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
LPA levels were determined using electrospray ionization
liquid chromatography tandem mass spectrometry (ESI-
LC/MS/MS) with an AB Sciex 5500 QTRAP hybrid triple
quadrupole/ion trap mass spectrometer coupled with an
Agilent 1200 liquid chromatography system. Lipids were
separated on Ascentis Express C8 (75 × 2.1 mm, 2.7 um)
column using methanol:water:HCOOH, 60:40:0.5, v/v
with 5 mM NH4COOH as solvent A and acetonitrile:
chloroform:water:HCOOH, 80:20:0.5:0.5, v/v with 5 mM
NH4COOH as solvent B. LPA molecular species were
analyzed in negative ionization mode with declustering
potential and collision energy optimized for each LPA mo-
lecular species. Individual saturated and unsaturated LPA
molecular species (16:0-, 17:0-, 18:0-, 18:1-, and 20:4-LPA,
all obtained from Avanti Polar Lipids, Inc., Alabaster, AL)
were used as reference compounds. 17:0-LPA was used
as the internal standard, and LPA quantitation was
performed by creating standard curves with variable
amounts of each available LPA molecular species versus
fixed amount of the internal standard (17:0-LPA). Total
lipid extract from fetal bovine serum was used as a source
of otherwise unavailable LPA molecular species to deter-
mine their chromatographic behavior and parameters of
ionization and collision-induced decomposition, and the
quantitation of these LPA molecular species was achieved
via the use of the best possible approximation from the
standard curves obtained with available individual LPA
standards. The identification of LPA molecular species
was achieved via monitoring for selected transitions from
molecular to product (m/z 153) ions specific for each LPA
molecular species, and by the analyte retention time iden-
tified by the available LPA standards and by comparing
with LPA extracted from bovine serum.
Statistical analyses
Statistical analysis was performed using Prism 6.0 (GraphPad
Software, Inc.). Differences in LPA levels between IPF
patients and controls were analyzed for statistical signifi-
cance using a two-tailed Student’s t-tests or Mann Whitney
tests for parametric and nonparametric data, respectively.
To adjust for multiple comparisons, we used the Bonferroni
method to calculate the accepted α (Type I) error rate for
each individual comparison performed, keeping the family-
wise error rate at 0.05. Therefore, for EBC LPA levels,
in which 9 different LPA species measured were mea-
sured, p values≤ 0.0055 (0.05/9) were considered sta-
tistically significant. For plasma LPA levels, in which 13
different LPA species were measured, p values≤0.0038
(0.05/13) were considered statistically significant.
Results
Patient characteristics
Relevant demographic and clinical data for IPF subjects
(n =11) and controls without lung disease (n = 11) on
whom EBC and plasma LPA measurements were per-
formed are summarized in Table 1. Of the 11 IPF sub-
jects, 6 were diagnosed by surgical lung biopsy, and 5
were diagnosed by clinical and radiographic criteria
alone. The mean age was 67.7 (+/− 8.5) years in the IPF
group and 68.2 (+/− 7.1) years in the control group. The
male to female ratio was 10:1 in the IPF group and 9:2
in the control group. There were no current smokers in
either group; however, both groups contained former
smokers. Spirometry data were available on 8/11 sub-
jects and DLCO (diffusion capacity of carbon monoxide)
data on 7/11 IPF subjects as shown in Table 1. Spirom-
etry was not obtained on control subjects. Of the avail-
able pulmonary function results, the majority of testing
(5/8) was performed on the day of EBC and plasma col-
lection. All pulmonary function testing was performed
within 15 days of sample collection. Supplemental oxy-
gen was needed for 7/11 of IPF subjects. None of the
IPF subjects were taking inhaled corticosteroids at the
time of data collection.
Levels of LPA in exhaled breath condensate and plasma
Nine different LPA species were detected in the EBC from
IPF subjects and controls (Table 2). Of these, docosate-
traenoyl (22:4) LPA exhibited a statistically significant
Table 1 Subject characteristics
IPF (n =11) Controls (n = 11)
Age (yrs) 67.7 (+/− 8.5) 68.2 (+/− 7.1)
Sex (M/F) 10/1 9/2
Smoking (current/ever/never) 0/8/3 0/9/2
FVC (% predicted) 60.5 (+/− 15.1) N/A
TLC (% predicted) 61.5 (+/− 8.1) N/A
DLCO [Hb] (% predicted) 43.7 (+/− 20.8) N/A
Data are presented as mean +/− SD as appropriate. N/A refers to data that
was not available or collected.
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nificantly higher in IPF patients compared to controls
(9.18 vs. 0.34 pM; p =0.001). Furthermore, there was min-
imal overlap between EBC 22:4 LPA levels in IPF patients
and controls. It was detected at levels>1.5 pM in 9/11
IPF patients but was undetectable in all but three of the
controls, and in only one control was the level>0.4 pM
(Figure 1). For the remaining eight LPA species, no statis-
tically significant differences were detected between the
two groups; however, there were trends towards increased
levels of 18:2 LPA and 20:3 LPA in EBC of IPF patients
(p = 0.13 and p =0.055, respectively). There was no sig-
nificant difference in the total amount of LPA in EBC be-
tween the two groups (664.69 +/− 83.03 vs. 766.15 +/−
137.35 pM, p =0.73). Thirteen different LPA species were
detected in plasma from IPF subjects and controls
(Table 3). None of these 13 species showed statistically
significant differences between the two groups, nor was
there a statistically significant difference in the total
amount of LPA between the two groups (mean control
LPA 77.90 +/− 22.31 nM and mean IPF 64.51 +/− 12.82
nM, p =0.10).
Docosatetraenoyl (22:4) LPA and subject characteristics
The average EBC 22:4 LPA level in IPF patients was
9.18 +/− 5.19 pM. There was no correlation between
22:4 LPA levels and disease severity, as determined by per-
cent predicted FVC or DLCO (data not shown). One sub-
ject had an EBC 22:4 LPA level of 60 pM, which far
exceeded the standard deviation of the mean. This subject
was a 46 year-old man with biopsy-proven usual intersti-
tial pneumonia (UIP) who required hospital admission for
worsening respiratory status in the setting of a suspected
IPF exacerbation. Spirometry performed during the pa-
tient’s hospitalization and within 10 days of EBC collection
demonstrated a severe restrictive deficit, with a FVC of
33% predicted. He subsequently developed respiratory fail-
ure and eventually underwent lung transplantation within
one month of sample collection. Pathologic review of the
explanted lung revealed UIP in the accelerated phase.
Table 2 LPA levels in Exhaled Breath Condensate (EBC)
LPA IPF Controls p-value
14:0 10.76 (2.54) 9.49 (1.79) 0.88
16:0 166.68 (33.74) 149.42 (20.53) > 0.99
18:0 359.99 (101.57) 312.70 (62.14) 0.78
18:1 15.81 (9.06) 9.00 (3.38) 0.76
18:2 9.19 (1.47) 5.93 (1.03) 0.13
20:2 40.37 (1.96) 40.03 (1.64) 0.83
20:3 153.43 (6.74) 137.77 (3.90) 0.055
20:5 0.00 (N/A) 0.73 (0.53) 0.48
22:4 9.18 (5.19) 0.34 (0.27) 0.0010
Total 766.15 (137.35) 664.69 (83.03) 0.73
Data are reported as mean concentration in pM (standard error).
AB
*
Figure 1 Exhaled breath condensate (EBC) LPA levels. Levels of docosatetraenoyl (22:4) LPA (A) and total LPA (B) in the exhaled breath
condensate (EBC) of IPF patients and controls, as determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Levels of 22:4
LPA, but not total LPA, were significantly higher in IPF patients vs. controls, with minimal overlap in EBC 22:4 LPA levels between the two groups.
*p =0.001 for the comparison of IPF vs. controls by Mann Whitney test.
Table 3 LPA levels in plasma
LPA IPF Controls p-value
14:0 0.11 (0.025) 0.19 (0.047) 0.11
16:0 6.05 (0.38) 6.93 (0.74) 0.29
16:1 0.66 (0.074) 0.97 (0.15) 0.071
18:0 3.69 (0.32) 3.46 (0.30) 0.60
18:1 5.10 (0.37) 6.05 (0.82) 0.29
18:2 19.40 (1.99) 24.56 (3.60) 0.21
20:2 0.54 (0.046) 0.56 (0.072) 0.74
20:3 3.13 (0.26) 3.64 (0.22) 0.16
20:4 11.89 (1.14) 13.96 (1.06) 0.20
20:5 1.55 (0.15) 2.31 (0.38) 0.051
22:4 0.92 (0.73) 0.88 (0.092) 0.70
22:5 2.98 (0.18) 3.10 (0.19) 0.67
22:6 10.06 (0.57) 11.29 (1.32) 0.39
Total 64.51 (3.87) 77.90 (7.05) 0.10
Data are reported as mean concentration in nM (standard error).
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the midst of IPF exacerbations during sample collection.
Discussion
LPA has emerged as an important pro-fibrotic mediator
in multiple organ systems, particularly the lungs, and
the first clinical trial of an LPA receptor antagonist has
recently been initiated in IPF patients (ClinicalTrials.gov
identifier: NCT01766817). In this study, we analyzed
the exhaled breath condensate (EBC) and plasma from
eleven IPF patients and eleven controls without lung dis-
ease for the presence of lysophosphatidic acid (LPA),
using liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS). We demonstrated that at least nine
LPA species are detectable in EBC, and that one of these
species, docosatetraenoyl (22:4) LPA, is significantly ele-
vated in the EBC of IPF patients compared to controls.
Thirteen LPA species were detectable in plasma; how-
ever, none of these differed significantly between the
two groups.
Multiple species of LPA exist in biological fluids and
are identified according to the composition of their fatty
acid side chain. While all LPA species are thought to sig-
nal through LPA receptors, there are data indicating that
the different species may have differing affinities for the
various receptors [33]. Very little is known about 22:4
LPA specifically, and it is unclear whether or not its sig-
naling profile differs significantly from that of other LPA
species. Notably, unsaturated LPA species appear to have
higher affinity for most LPA receptors than do saturated
species [34]. In particular, long chain, polyunsaturated
LPA species (like 22:4 LPA) have been shown to be the
most potent activators of certain biological processes,
such as platelet activation [35]. Therefore, it is possible
that 22:4 LPA may have more potent pro-fibrotic effects
compared to other LPA species, and that the increase in
22:4 LPA in the EBC of IPF patients may be playing a
role in driving the disease process. It should be noted,
however, that the amount of 22:4 LPA in EBC was only
a small fraction of total LPA, which may argue against a
significant pathophysiological role for this particular
LPA species in IPF. The increase in 22:4 LPA may in-
stead indicate the generation of LPA from a specific a
specific source, such as lung epithelial cells, which are
known to contain high levels of polyunsaturated phos-
pholipids [36].
In addition to being a therapeutic target, LPA may also
serve as a useful biomarker for IPF. Elevations in LPA
have been detected in the bronchoalveolar lavage (BAL)
fluid from mice after intratracheal bleomycin adminis-
tration and from humans with known IPF [13]. 22:4 LPA
was not specifically measured in this previous report of
IPF patients, but it is detectable in BAL fluid, and it and
other long-chain, polyunsaturated LPA species have
been found to be elevated in BAL fluid in a mouse
model of asthma and in human allergic airway inflam-
mation [37,38]. Our data suggest that EBC 22:4 LPA
levels may be a useful biomarker for IPF diagnosis and/or
prognosis. From a diagnostic standpoint, our data demon-
strate minimal overlap between EBC 22:4 LPA levels in
IPF patients and controls. To be of true value in the diag-
nosis of IPF, EBC 22:4 LPA levels would have to be able
to differentiate between IPF and other forms of chronic
interstitial lung diseases, most notably nonspecific intersti-
tial pneumonia (NSIP) and chronic hypersensitivity pneu-
monitis (HP). As such comparisons were not performed
in this study, further research would be needed to fully
evaluate the potential role of EBC 22:4 LPA levels as a
diagnostic biomarker in IPF.
It is notable that the EBC 22:4 LPA level in one patient
was far outside the standard deviation of the mean, and
that this patient was in the midst of an IPF exacerbation
at the time of sample collection. This observation raises
the hypothesis that EBC 22:4 LPA levels may be a useful
biomarker of disease activity and/or acute exacerbations
in IPF. Analysis of our data failed to reveal an associ-
ation between EBC 22:4 LPA levels and disease severity
or outcomes (decline in pulmonary function or mortal-
ity), although this study was likely underpowered to de-
tect any such associations. Further study of EBC LPA
levels in IPF, specifically in patients with rapidly progres-
sive disease and those suffering from acute exacerba-
tions, may shed light on the potential role of EBC 22:4
LPA levels as a prognostic biomarker in this disease.
While BAL has long been considered the optimal
means of sampling the alveolar surfaces for analysis, it is
invasive and not without risk, especially in subgroups of
patients with advanced respiratory disease, such as those
with pulmonary fibrosis. In comparison, EBC provides a
method for non-invasive sampling of the lower respira-
tory tract. There are concerns regarding the accuracy
with which EBC reflects the distal lung microenviron-
ment, however, as there is risk of contamination with
oral and gastrointestinal secretions, as well as an un-
known (and potentially variable) dilution factor due to
condensed water vapor [24]. Recommendations regard-
ing optimized EBC collection have been made to
minimize contamination and variations in solute dilution
[24,29]. In our current study, it is reassuring that the
two most abundant LPA species detected in EBC (16:0
and 18:0) were also the two most abundant species mea-
sured in BAL fluid from control subjects in the IPF (un-
published data) and asthma studies referenced above,
suggesting that our EBC samples accurately reflect the
distal lung compartments [38]. Furthermore, the total
LPA levels in our EBC samples are similar to those seen
in BAL fluid, with respect to both the mean values and
the standard deviations, suggesting that the dilution
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these two sample types [37].
Additional limitations to this study exist. Most notably,
the sample size of the study was small. Though we were
able to detect a difference in the amount of 22:4 LPA in
IPF subjects versus controls, we were likely underpowered
to detect differences in the other LPA species should any
exist. While the subjects in the study population of inter-
est all met current consensus guidelines for diagnosis of
IPF, they differed in disease severity. Whether or not sig-
nificant differences in LPA species could be detected when
stratified for disease severity is not known. However, des-
pite our limitations, we were able to detect a significant
elevation in the amount of 22:4 LPA in EBC from IPF sub-
jects. This study builds on previous work showing that
LPA is increased in BAL fluid in IPF patients [13], and ad-
vances the current field of pulmonary research by showing
that LPA can be extracted from EBC. Additional research
is needed to determine any relationships between LPA
species detectable in EBC and disease severity or progres-
sion in IPF.
Conclusions
LPA is detectable in exhaled breath condensate (EBC),
and 22:4 LPA levels are elevated in the EBC of IPF pa-
tients compared to controls.
Abbreviations
IPF: Idiopathic pulmonary fibrosis; LPA: Lysophosphatidic acid; EBC: Exhaled
breath condensate; BAL: Bronchoalveolar lavage; LC-MS/MS: Liquid
chromatography-tandem mass spectrometry; FVC: Forced vital capacity;
DLCO: Diffusion capacity of carbon monoxide.
Competing interests
AMT has applied for the following patent: U.S. Patent Application, 12/450,051,
filed September 9, 2009, “Lysophosphatidic Acid Receptor Targeting for the
Treatment of Lung Disease”.
Authors’ contributions
SBM assisted in data collection, performed statistical analyses, and prepared
the draft of the manuscript. SKM and LNB assisted in subject enrollment and
performed clinical data collection and analyses. IG and EVB performed lipid
extraction and measurement of LPA species by LC-MS/MS. BSS and AMT
designed and oversaw all aspects of this study. All authors read and
approved of the final manuscript.
Acknowledgements
The authors gratefully acknowledge that these studies were supported by
U.S. National Institutes of Health grants K08-HL105656 (to B.S.S) and R01-
HL108975 (to A.M.T.). The authors thank S. Engelstad, J. Oakley, and the rest
of the staff in the Massachusetts General Hospital Clinical Research Program
for their assistance with this study.
Author details
1Pulmonary and Critical Care Unit, Massachusetts General Hospital and
Harvard Medical School, Boston, MA, USA.
2Center for Immunology and
Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical
School, Boston, MA, USA.
3Division of Pulmonary Sciences and Critical Care
Medicine, University of Colorado Denver, Aurora, CO, USA.
4Department of
Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Received: 6 January 2014 Accepted: 14 January 2014
Published: 27 January 2014
References
1. Selman M: Idiopathic Pulmonary Fibrosis: Prevailing and Evolving
Hypotheses about Its Pathogenesis and Implications for Therapy. Ann
Intern Med 2001, 134:136–151.
2. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med
2001, 345:517–525.
3. Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V,
Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C,
Verbeken E, Verschakelen JA, Wells AU, Verleden GM: The pathogenesis of
pulmonary fibrosis: a moving target. Eur Respir J 2013, 41:1207–1218.
4. Ley B, Collard HR, King TE: Clinical course and prediction of survival in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011,
183:431–440.
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV,
Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU,
Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T,
Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L,
Selman M, Dudden RF, et al: An official ATS/ERS/JRS/ALAT statement:
idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
management. Am J Respir Crit Care Med 2011, 183:788–824.
6. Coward WR, Saini G, Jenkins G: The pathogenesis of idiopathic pulmonary
fibrosis. Ther Adv Respir Dis 2010, 4:367–388.
7. Shea BS, Tager AM: Role of the lysophospholipid mediators
lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.
Proc Am Thorac Soc 2012, 9:102–110.
8. Baker DL, Umstot ES, Desiderio DM, Tigyi GJ: Quantitative analysis of
lysophosphatidic acid in human blood fractions. Ann N Y Acad Sci 2000,
905:267–269.
9. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA,
Pradère JP, Pettit TR, Wakelam MJO, Saulnier-Blache J-S, Mummery CL,
Moolenaar WH, Jonkers J: Autotaxin, a secreted lysophospholipase D,
is essential for blood vessel formation during development. Mol Cell Biol
2006, 26:5015–5022.
10. Albers HMHG, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW,
Schuurman K, van Tellingen O, Morris AJ, Smyth SS, Moolenaar WH, Ovaa H:
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in
the circulation. Proc Natl Acad Sci U S A 2010, 107:7257–7262.
11. Moolenaar WH, van Meeteren LA, Giepmans BNG: The ins and outs of
lysophosphatidic acid signaling. Bioessays 2004, 26:870–881.
12. Davenport AP, Alexander SPH, Sharman JL, Pawson AJ, Benson HE,
Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP,
Spedding M, Harmar AJ: International Union of Basic and Clinical
Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations
for new pairings with cognate ligands. Pharmacol Rev 2013, 65:967–986.
13. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z,
Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, Hart WK, Pardo A, Blackwell TS,
Xu Y, Chun J, Luster AD: The lysophosphatidic acid receptor LPA1 links
pulmonary fibrosis to lung injury by mediating fibroblast recruitment and
vascular leak. Nat Med 2008, 14:45–54.
14. Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS,
Chun J, Luster AD, Tager AM: Amelioration of dermal fibrosis by genetic
deletion or pharmacologic antagonism of lysophosphatidic acid
receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011,
63:1405–1415.
15. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, Tejima K,
Nishikawa T, Arai M, Yanase M, Aoki J, Arai H, Omata M, Fujiwara K, Yatomi Y:
Plasma lysophosphatidic acid level and serum autotaxin activity are
increased in liver injury in rats in relation to its severity. Life Sci 2007,
81:1009–1015.
16. Sakai N, Chun J, Duffield JS, Wada T, Luster AD, Tager AM: LPA1-induced
cytoskeleton reorganization drives fibrosis through CTGF-dependent
fibroblast proliferation. FASEB J 2013, 27:1830–1846.
17. Pradère JP, Klein J, Gres S, Guigné C, Neau E, Valet P, Calise D, Chun J,
Bascands J-L, Saulnier-Blache J-S, Schanstra JP: LPA1 receptor activation
promotes renal interstitial fibrosis. J Am Soc Nephrol 2007, 18:3110–3118.
18. Funke M, Zhao Z, Xu Y, Chun J, Tager AM: The lysophosphatidic acid
receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J
Respir Cell Mol Biol 2012, 46:355–364.
19. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC,
Fagan P, Baccei CS, Santini AM, Hutchinson JH, Seiders TJ, Parr TA, Prasit P,
Evans JF, Lorrain DS: A novel, orally active LPA(1) receptor antagonist
Montesi et al. BMC Pulmonary Medicine 2014, 14:5 Page 6 of 7
http://www.biomedcentral.com/1471-2466/14/5inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol
2010, 160:1699–1713.
20. Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, Garcia JGN, Chun J,
Natarajan V: Lysophosphatidic Acid Receptor 2 Deficiency Confers
Protection Against Bleomycin-Induced Lung Injury and Fibrosis in Mice.
Am J Respir Cell Mol Biol 2013, 49:912–922.
21. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ,
Sheppard D, Jenkins G: Lysophosphatidic acid induces alphavbeta6
integrin-mediated TGF-beta activation via the LPA2 receptor and the
small G protein G alpha(q). Am J Pathol 2009, 174:1264–1279.
22. Kazani SS, Israel EE: Utility of exhaled breath condensates across
respiratory diseases. Am J Respir Crit Care Med 2012, 185:791–792.
23. Antczak A, Piotrowski W, Marczak J, Ciebiada M, Gorski P, BARNES PJ:
Correlation between eicosanoids in bronchoalveolar lavage fluid and in
exhaled breath condensate. Dis Markers 2011, 30:213–220.
24. Effros RMR, Casaburi RR, Porszasz JJ, Morales EME, Rehan VV: Exhaled breath
condensates: analyzing the expiratory plume. Am J Respir Crit Care Med
2012, 185:803–804.
25. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, Wechsler
ME, Levy BD, Israel E: Exhaled breath condensate eicosanoid levels
associate with asthma and its severity. J Allergy Clin Immunol 2013,
132:547–553.
26. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Górski P:
Exhaled eicosanoids and biomarkers of oxidative stress in
exacerbation of chronic obstructive pulmonary disease. Arch Med Sci
2012, 8:277–285.
27. Chow SS, Thomas PSP, Malouf MM, Yates DHD: Exhaled breath
condensate (EBC) biomarkers in pulmonary fibrosis. JB r e a t hR e s2012,
6:016004–016014.
28. Psathakis KK, Mermigkis DD, Papatheodorou GG, Loukides SS, Panagou PP,
Polychronopoulos VV, Siafakas NMN, Bouros DD: Exhaled markers of
oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest 2006,
36:362–367.
29. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van
Beurden WJC, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R,
Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q,
Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE,
Reinhold P, van Rensen ELJ, Rubinstein I, Silkoff P, et al: Exhaled breath
condensate: methodological recommendations and unresolved
questions. Eur Respir J 2005, 26:523–548.
30. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH: The bioactive
phospholipid lysophosphatidic acid is released from activated platelets.
Biochem J 1993, 291(Pt 3):677–680.
31. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 1959, 37:911–917.
32. Berdyshev EV, Gorshkova IA, Usatyuk P, Zhao Y, Saatian B, Hubbard W,
Natarajan V: De novo biosynthesis of dihydrosphingosine-1-phosphate
by sphingosine kinase 1 in mammalian cells. Cell Signal 2006,
18:1779–1792.
33. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K: Lysophosphatidic
acid (LPA) receptors of the EDG family are differentially activated by LPA
species. Structure-activity relationship of cloned LPA receptors. FEBS Lett
2000, 478:159–165.
34. Tigyi G: Aiming drug discovery at lysophosphatidic acid targets. Br J
Pharmacol 2010, 161:241–270.
35. Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T,
Satouchi K, Waku K, Fukuzawa K: Human platelets respond
differentially to lysophosphatidic acids having a highly unsaturated
fatty acyl group and alkyl ether-linked lysophosphatidic acids.
Biochem J 2002, 365:617–628.
36. Berry KAZ, Li B, Reynolds SD, Barkley RM, Gijón MA, Hankin JA, Henson PM,
Murphy RC: MALDI imaging MS of phospholipids in the mouse lung.
J Lipid Res 2011, 52:1551–1560.
37. Georas SN, Berdyshev E, Hubbard W, Gorshkova IA, Usatyuk PV, Saatian B,
Myers AC, Williams MA, Xiao HQ, Liu M, Natarajan V: Lysophosphatidic acid
is detectable in human bronchoalveolar lavage fluids at baseline and
increased after segmental allergen challenge. Clin Exp Allergy 2007,
37:311–322.
38. Park GY, Lee YG, Berdyshev E, Nyenhuis S, Du J, Fu P, Gorshkova IA, Li Y,
Chung S, Karpurapu M, Deng J, Ranjan R, Xiao L, Jaffe HA, Corbridge SJ,
Kelly EAB, Jarjour NN, Chun J, Prestwich GD, Kaffe E, Ninou I, Aidinis V,
Morris AJ, Smyth SS, Ackerman SJ, Natarajan V, Christman JW: Autotaxin
production of lysophosphatidic acid mediates allergic asthmatic
inflammation. Am J Respir Crit Care Med 2013, 188:928–940.
doi:10.1186/1471-2466-14-5
Cite this article as: Montesi et al.: Docosatetraenoyl LPA is elevated in
exhaled breath condensate in idiopathic pulmonary fibrosis. BMC
Pulmonary Medicine 2014 14:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Montesi et al. BMC Pulmonary Medicine 2014, 14:5 Page 7 of 7
http://www.biomedcentral.com/1471-2466/14/5